Prognosis
Aspen Agrees to Make J&J Covid-19 Vaccine in South Africa
- Africa’s no. 1 drugmaker has deal for 300 million doses/year
- J&J’s candidate resumed clinical trials after pause last month
This article is for subscribers only.
Aspen Pharmacare Holdings Ltd. agreed to make the Covid-19 vaccine candidate being developed by Johnson & Johnson at a factory in South Africa, a move that could help with distribution on a continent with otherwise limited manufacturing capacity.
Africa’s biggest drugmaker has the capacity to produce 300 million doses a year at the plant in Port Elizabeth if the shot is approved, the company said in a statement on Monday. J&J’s experimental inoculation against the virus that’s swept the world this year is still in clinical trials, after a brief pause last month after a patient became sick.